The clinical relevance of native vitamin D in pediatric kidney disease

Banerjee, Sushmita; Sengupta, Jayati; Basu, Surupa

doi:10.1007/s00467-022-05698-9

Cited by 2 publications

(1 citation statement)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Taking into account that serum 25(OH)D level <20 ng/mL indicates VD deficiency, and >30 ng/mL is needed for optimal health, the Kidney Disease Outcomes Quality Initiative (KDOQI) and Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend measuring 25(OH)D levels once a year in children with CKD stages 2-5 and starting supplementation if levels are <30 ng/mL (7). The KDOQI guidelines also recommend the administration of cholecalciferol for treating VD failure in CKD stages 3 and 4, and active VD hormone for VD deficiency in patients with stage 5 CKD who also have secondary hyperparathyroidism.…”

Section: Introductionmentioning

confidence: 99%

Vitamin D levels in the pre- and post-COVID-19 pandemic periods in pediatric patients with chronic kidney disease

Parra-Ortega,

Zurita-Cruz,

Ortiz-Flores

et al. 2023

Front. Nutr.

View full text Add to dashboard Cite

IntroductionVitamin D (VD) deficiency is common in children with chronic kidney disease (CKD) because of multiple factors. During the coronavirus disease 2019 (COVID-19) pandemic, it increased because of medicine shortage and no enough medical service for patients with non-COVID-19 diseases.ObjectiveTo analyze the effects of the COVID-19 pandemic-related lockdown on the serum levels and status of 25-hydroxyvitamin D3 (25-[OH]D) in children with CKD.Materials and methodsThis retrospective study included patients (6–18 years old) who were diagnosed with CKD stage 2–5 and routinely measured for serum VD levels between May 2019 and December 2022. Serum 25-(OH)D levels were measured before, during, and after the pandemic (2019, 2020–2021, and 2022, respectively). The daily dose of cholecalciferol supplementation and the readjustment (if required) were recorded.ResultsThis study included 171 patients (median age: 12 years). Before the pandemic, the median serum VD level was 25.0 ng/mL (19.3% VD deficiency). Then, VD supplementation was adjusted to 400–1,200 UI daily in 98.8% (n = 169) of patients. During the pandemic, the median VD level decreased to 22.5 ng/mL (43.3% VD deficiency). Hence, the supplementation was readjusted, and after the pandemic, the level was 28.7 ng/mL (18.7% VD deficiency), indicating a statistically significant increase in serum VD levels from the prepandemic period (p = 0.007).ConclusionDecreased serum VD levels and increased VD deficiency frequency were observed in patients with CKD during the COVID-19 but improved after readjustment of supplementation.

show abstract

Section: Introductionmentioning

confidence: 99%

Vitamin D levels in the pre- and post-COVID-19 pandemic periods in pediatric patients with chronic kidney disease

Parra-Ortega,

Zurita-Cruz,

Ortiz-Flores

et al. 2023

Front. Nutr.

View full text Add to dashboard Cite

show abstract

Cardiometabolic factors and vitamin D deficiency in pediatric patients with chronic kidney disease

Parra-Ortega,

Zurita-Cruz,

Villasis-Keever

et al. 2024

Front. Nutr.

View full text Add to dashboard Cite

BackgroundPatients with chronic kidney disease (CKD) are at increased risk for cardiovascular disease. Up to 80% of patients with CKD may exhibit inadequate vitamin D (VD) levels, which have been linked to the presence of cardiometabolic factors (CFs) in the adult population. However, research on this association in the pediatric population is limited.ObjectiveTo analyze the effects of 25-hydroxyvitamin D3 (25-[OH]D) levels and status on the presence of CFs in children receiving kidney replacement therapy (KRT).Materials and methodsThis cross-sectional study included pediatric patients receiving KRT, aged 8–17 years, who were receiving hemodialysis or peritoneal dialysis from January 2021 to March 2024. We conducted anthropometric measurements, blood pressure assessments, and glucose, 25-(OH)D, and lipid profiling for all participants. The daily dose of cholecalciferol supplementation, as well as other medications affecting bone and lipid metabolism and antihypertensive drugs, were documented. Statistical analyses were performed using Student’s t-tests and chi-square tests to compare the CFs between groups with and without VD deficiency.ResultsThe study involved 156 patients with an average age of 12.9 years and a mean serum VD level of 22.5 ng/dL. Patients with VD deficiency presented higher levels of total cholesterol and diastolic blood pressure (p < 0.05). No statistically significant differences were found in other biochemical profile variables or in the frequency of cardiometabolic factors.ConclusionVitamin D deficiency seems to increase the risk of dyslipidemia and uncontrolled hypertension in children and adolescents with end-stage CKD.

show abstract

The clinical relevance of native vitamin D in pediatric kidney disease

Cited by 2 publications

References 105 publications

Vitamin D levels in the pre- and post-COVID-19 pandemic periods in pediatric patients with chronic kidney disease

Vitamin D levels in the pre- and post-COVID-19 pandemic periods in pediatric patients with chronic kidney disease

Cardiometabolic factors and vitamin D deficiency in pediatric patients with chronic kidney disease

Contact Info

Product

Resources

About